Christine P. Clark

Christine P. Clark is an Associate at Walsh Pizzi O'Reilly Falanga LLP, where her practice focuses on business and commercial litigation, with a recognized specialty in patent litigation. She has consistently represented plaintiffs in pharmaceutical patent disputes, as evidenced by all three of her tracked appearances being on the plaintiff side. Her patent litigation experience primarily involves Hatch-Waxman litigation, representing innovator pharmaceutical companies.

Ms. Clark has served as local counsel for Astellas Pharma Inc. in several key pharmaceutical patent cases. Notably, in Astellas Pharma Inc. v. Ascent Pharmaceuticals, Inc., a federal judge ruled in March 2026 that Ascent's proposed generic copies of Astellas's Myrbetriq ER infringed four patents, delaying their launch until 2030. This decision is currently under appeal at the Federal Circuit. She also represented Astellas Pharma Inc. in Astellas Pharma Inc. et al. v. Haimen Pharma Inc. et al., an infringement lawsuit concerning patents related to enzalutamide (Xtandi®), which was dismissed with prejudice in January 2026.

Christine Clark was admitted to the New Jersey bar in 2022. She earned her J.D. from Seton Hall University School of Law in 2022 and her BBA in Marketing from the University of Notre Dame in 2017. No public record of her involvement in PTAB or IPR proceedings was found.